Jazz Pharmaceuticals plc (JAZZ) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Jazz Pharmaceuticals plc (JAZZ): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 65/100 — a percentile rank of Jazz Pharmaceuticals plc’s fundamentals against Manufacturing peers, weakest on financial health. A quality ranking, not a price prediction.
| Market cap | $15.1B |
| P / E | 16.1× |
| P / S | 3.3× |
| EV / EBITDA | 11.1× |
| Gross margin | 88.4% |
| Operating margin | 16.8% |
| Net margin | 20.4% |
| Return on equity | 19.6% |
| ROIC | 13.3% |
| Revenue growth | 12.6% |
| Debt / equity | 0.9× |
| Dividend yield | 0.0% |
Is Jazz Pharmaceuticals plc overvalued? P/E looks fair vs its 5-year range; P/S looks overvalued vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Jazz Pharmaceuticals plc’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact